Ninety-Day Overall Healthcare Reimbursements and Their Drivers for Primary Arthroscopic Bankart Repair
- 1From the Yale Department of Orthopaedics and Rehabilitation, New Haven, CT (Sanchez, Dr. Smith-Voudouris, Zehner, Dr. Halperin, Dr. Duah, and Dr. Grauer), and the Department of Orthopaedic Surgery and Rehabilitation, Loyola University Medical Center, Maywood, Illinois (Christiansen, and Dr. Mulcahey).
Abstract
Background:: Arthroscopic Bankart repair (ABR) is a widely performed procedure for anterior glenohumeral instability. The aim of this study was to characterize variability and identify drivers of 90-day healthcare reimbursement after primary ABR.
Methods:: Primary ABR patients were identified in the PearlDiver M170 database (January 2010–April 2023). Patients who were inactive within 90 days preoperatively or postoperatively or who were coded for neoplasm or infection within 90 days preoperatively were excluded. Variables analyzed included patient characteristics (age, sex, Elixhauser Comorbidity Index [ECI]), nonclinical factors (insurance plan, geographic region), postoperative events (any adverse event [AAE], emergency department [ED] visit, hospital readmission), and total 90-day reimbursements. Multivariable linear regression was conducted to identify independent predictors of reimbursement.
Results:: Overall, 135,144 primary ABR patients were identified, representing $596,112,149 in total reimbursements. The mean ± SD reimbursement was $4450 ± $5268. The median (25th quartile–75th quartile) reimbursement was $3192 (1751–5465).
Variables independently associated with the greatest 90-day reimbursement were readmission (+18060), AAE (+1169), and ED visit (1044). Weaker associations were observed for geographic region, ECI, and male sex (P < 0.0001 for all). Compared with commercial insurance, Medicare (–2072) and Medicaid (–$1371) were associated with lower reimbursement (P < 0.0001 for both). Notably, over the course of the study period, median overall reimbursement increased from $1930 to $3540 (P < 0.0001).
Conclusion:: This longitudinal, national analysis identified cost variability and key drivers related to ABR. Preventing readmissions may yield the largest cost reductions while observed disparities across insurance plans and regions highlight opportunities for standardization and equity in reimbursement.
Related
- Development and temporal validation of nomograms and machine learning models for predicting overall and cancer-specific survival in primary distal cholangiocarcinoma: a SEER-based study
- Association between primary-site surgery and overall survival in non-metastatic and metastatic colorectal cancer: a population-based study using the Surveillance, Epidemiology, and End Results database
- Lower lung donor PaO2/FiO2 ratio correlates with early primary graft dysfunction, but does not impact overall survival after lung transplantation: a dual center study
- Failure Analysis in Patients With Recurrent Anterior Shoulder Instability After Primary Arthroscopic Capsulolabral Repair
- Bayesian Stacking of Quantitative Adverse Outcome Pathways Isolates Primary Drivers of Liver Steatosis
BibTeX
@article{sanchez2026ninetyday,
title = {{Ninety-Day Overall Healthcare Reimbursements and Their Drivers for Primary Arthroscopic Bankart Repair}},
author = {Joshua G. Sanchez and Julian Smith-Voudouris and Katie M. Zehner and Scott J. Halperin and Bianca A. Duah and Mitchell J. Christiansen and Mary K. Mulcahey and Jonathan N. Grauer},
journal = {Journal of the American Academy of Orthopaedic Surgeons. Global research \& reviews},
year = {2026},
month = nov,
doi = {10.5435/jaaosglobal-d-25-00419},
url = {https://europepmc.org/article/PMC/PMC13722497},
note = {CC BY-ND},
}
RIS
TY - JOUR
TI - Ninety-Day Overall Healthcare Reimbursements and Their Drivers for Primary Arthroscopic Bankart Repair
AU - Joshua G. Sanchez
AU - Julian Smith-Voudouris
AU - Katie M. Zehner
AU - Scott J. Halperin
AU - Bianca A. Duah
AU - Mitchell J. Christiansen
AU - Mary K. Mulcahey
AU - Jonathan N. Grauer
PY - 2026
DA - 2026/11/01
JO - Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
DO - 10.5435/jaaosglobal-d-25-00419
UR - https://europepmc.org/article/PMC/PMC13722497
AB - Background:: Arthroscopic Bankart repair (ABR) is a widely performed procedure for anterior glenohumeral instability. The aim of this study was to characterize variability and identify drivers of 90-day healthcare reimbursement after primary ABR. Methods:: Primary ABR patients were identified in the PearlDiver M170 database (January 2010–April 2023). Patients who were inactive within 90 days preoperatively or postoperatively or who were coded for neoplasm or infection within 90 days preoperatively were excluded. Variables analyzed included patient characteristics (age, sex, Elixhauser Comorbidity Index [ECI]), nonclinical factors (insurance plan, geographic region), postoperative events (any adverse event [AAE], emergency department [ED] visit, hospital readmission), and total 90-day reimbursements. Multivariable linear regression was conducted to identify independent predictors of reimbursement. Results:: Overall, 135,144 primary ABR patients were identified, representing $596,112,149 in total reimbursements. The mean ± SD reimbursement was $4450 ± $5268. The median (25th quartile–75th quartile) reimbursement was $3192 (1751–5465). Variables independently associated with the greatest 90-day reimbursement were readmission (+18060), AAE (+1169), and ED visit (1044). Weaker associations were observed for geographic region, ECI, and male sex (P < 0.0001 for all). Compared with commercial insurance, Medicare (–2072) and Medicaid (–$1371) were associated with lower reimbursement (P < 0.0001 for both). Notably, over the course of the study period, median overall reimbursement increased from $1930 to $3540 (P < 0.0001). Conclusion:: This longitudinal, national analysis identified cost variability and key drivers related to ABR. Preventing readmissions may yield the largest cost reductions while observed disparities across insurance plans and regions highlight opportunities for standardization and equity in reimbursement.
SN - 2474-7661
ER -